Shots:
- Chi-Med to receive ~$95M and ~$135M as development & commercial milestones along with royalties on commercialization of each drug candidates. Inmagene to get an exclusive option for four drug candidates solely for immunological diseases
- If Inmagene exercises the option, it will get the right to further develop, manufacture and commercialize the specific drug candidate globally, with Chi-Med retaining the first right to co-commercialization it in mainland China
- The companies will work together to move the drug candidates towards IND submission. If successful, Inmagene will further lead drug candidates through global clinical development
Click here to read full press release/ article | Ref: ChiMed | Image: Inmagenebio
The post Chi-Med and Inmagene Collaborate to Develop Therapies for Immunological Diseases first appeared on PharmaShots.
